Munich, November, 26th 2008

The Supervisory Board of Curacyte AG, a Munich-based drug development company, has appointed Dr. Ulrich Delvos as its new Chief Executive Officer. He is joining from MediGene AG where he served as Chief Operating Officer for nearly four years until May 2008.

Simultaneously, Dr. Helmut Giersiefen who led Curacyte since 1999 stepped down as CEO to join The Medicines Company in an executive management function.

In August 2008, The Medicines Company had acquired Curacyte’s wholly-owned subsidiary, Curacyte Discovery GmbH. The proceeds of this transaction are used by Curacyte AG and its wholly-owned US subsidiary, Apex Bioscience, Inc. (Chapel Hill, North Carolina) to continue the development of Curacyte’s lead product Hemoximer (Pyridoxalated Hemoglobin Polyoxyethylene, PHP). A pivotal Phase III study to be conducted in patients suffering from distributive shock and not responding to standard therapy with catecholamines is currently being inititated in various European countries.

“We are pleased that we could attract Dr. Delvos to Curacyte. He is an experienced manager with an impressive track record in drug development in the pharmaceutical as well as the biotech industry and is ideally suited to advance Curacyte’s ambitious core program”, commented Dr. Helmut M. Schuehsler, Chairman of Curacyte’s Supervisory Board and Managing Partner of TVM Capital. He continued: “Furthermore, I wholeheartedly thank Dr. Giersiefen for his excellent and successful work for the company over the last eight years. He has made critical contributions to advancing our lead drug Hemoximer into Phase III and build additional value in the company that has led to the attractive deal with The Medicines Company. We wish him well and success in his new position. We are also looking forward to having him join the Supervisory Board of Curacyte in the near future.”

About Dr. Delvos:
Dr. Delvos has more than twenty years of experience in leading positions in the industry. Prior to joining Curacyte he managed the R&D activities of listed biotech-company MediGene AG in Munich and served as Senior Vice President and Chief Scientific Officer of Aventis Behring in King of Prussia, PA, USA. A Medical Doctor by training he first pursued an academic career at the University of Münster, worked as Postdoc at the University of Washington in Seattle, WA and later as Senior Scientist in a Clinical Research Group of the Max-Planck-Society. His thesis in “ Experimental Medicine” was accepted at the University of Giessen, where he lectured as an associate professor while working for Behringwerke AG, a subsidiary of the former Hoechst Group. At Behringwerke he held various management positions, such as Head of Clinical Research, Head of R&D and finally, Managing Director of the “spin-out” Centeon, comprising the plasma protein-business of the company.

About Curacyte:
Curacyte AG is an advanced biopharmaceutical company dedicated to the development of new therapeutics for acute and critical care.
Curacyte’s lead product is Hemoximer (Pyridoxalated Hemoglobin Polyoxyethylene, PHP). Hemoximer has been developed as a scavenger of nitirc oxide, the causative agent responsible for vasodilation hypotension in shock.The ability to scavenge and metabolize NO is one of the important physiological functions of natural hemoglobin. Hemoximer has been demonstrated to reverse vasodilation and resolve hypotension associated with distributive shock and has completed the Phase II clinical development in this primary indication. Currently, a pivotal Phase III study to be conducted in patients suffering from distributive shock and not responding to standard therapy with catecholamines is being inititated in various European countries. Apart from distributive shock, hemoximer is also being studied as an adjunct to high-dose interleukin-2 (IL-2) for patiens with metastatic melanoma and renal cell carcinoma. Shock is a frequent dose-limiting side effect of high-dose IL-2 therapy.